Amber Salzman

Amber Salzman is the founder of Annapurna Therapeutics SAS, which was founded in 2012.
She held the title of President & Chief Executive Officer from 2012 to 2016.
Currently, she is the President, Chief Executive Officer & Director at Ohana Biosciences, Inc., the Chief Executive Officer at Epicrispr Biotechnologies, Inc., the Director at Drexel University School of Public Health, the Director at Ald Connect, Inc., a Non-Executive Director at AviadoBio Ltd., and a Trustee at Lankenau Institute for Medical Research.
She is also the President of The Stop ALD Foundation since 2001.
In her former positions, she was the President & Chief Executive Officer of CardioKine, Inc. from 2009 to 2011, the President, Chief Executive Officer & Director of Adverum Biotechnologies, Inc. from 2016 to 2018, and a Director at Akcea Therapeutics, Inc. in 2020.
She was also a Member-Research & Development Executive Team at GSK Plc.
Dr. Salzman holds a doctorate degree from Bryn Mawr College and an undergraduate degree from Temple University (Pennsylvania).